In recent years, therapies selectively targeting cell signaling pathways, such as VEGF, EGFR, KRAS, BRAF, ALK, HER2, MET, TITF-1, p53, and LKB1, have both provided a better understanding of NSCLC and have been used as prognostic factors or targets for individualized therapy[8]. Here, VEGFA is linked to non-small cell lung carcinoma.